[关键词]
[摘要]
目的 探讨人参多糖注射液联合表柔比星治疗乳腺癌的临床疗效。方法 选取2016年2月—2017年2月在临沂市肿瘤医院治疗的乳腺癌患者78例,根据治疗用药的差别分为对照组(39例)和治疗组(39例)。对照组静脉滴注注射用盐酸表柔比星,每个疗程第1天给予90 mg/m2,1次/3周;治疗组在对照组基础上静脉滴注人参多糖注射液,4 mL/次,2次/d。两组均治疗6周。观察两组患者临床疗效,同时比较治疗前后两组患者肿瘤标志物水平、血清细胞因子水平和不良反应情况。结果 治疗后,对照组客观缓解率(ORR)和临床获益率(CBR)分别为35.90%和69.23%,均分别明显低于治疗组的58.97%和87.18%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清糖抗原125(CA125)、糖抗原153(CA153)、癌胚抗原(CEA)、肿瘤坏死因子-α(TNF-α)、可溶性CD105(S-CD105)和转化生子因子-β1(TGF-β1)水平均显著降低(P<0.05),干扰素-γ(IFN-γ)和白细胞介素-12(IL-12)水平显著升高(P<0.05),且治疗组上述肿瘤标志物和细胞因子水平明显优于对照组(P<0.05)。治疗期间,治疗组不良反应发生率明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论 人参多糖注射液联合表柔比星治疗乳腺癌可有效降低机体肿瘤标志物水平和改善机体细胞因子表达水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Ginseng Polysacchride Injection combined with epirubicin in treatment of breast cancer. Methods Patients (78 cases) with breast cancer in Linyi Cancer Hospital from February 2016 to February 2017 were divided into control (39 cases) and treatment (39 cases) groups based on different treatments. Patients in the control group were iv administered with Epirubicin Hydrochloride for injection, 90 mg/m2 for the first day of each course of treatment, once every three weeks. Patients in the treatment group were iv administered with Ginseng Polysacchride Injection on the basis of the control group, 4 mL/time, twice daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the tumor markers, the serological indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate in the control group were 35.90% and 69.23%, which were significantly lower than 58.97% and 87.18% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the CA125, CA153, CEA, TNF-α, S-CD105 and TGF-β1 levels in two groups were significantly decreased (P < 0.05), But IFN-γ and IL-12 levels were significantly increased (P < 0.05), and the tumor markers, the serological indexes in the treatment group after treatment were significantly better than those in the control group (P < 0.05). During the treatment, the adverse reactions rate in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Ginseng Polysacchride Injection combined with epirubicin in treatment of breast cancer can effectively reduce the level of tumor markers and improve the cytokines expression, which has a certain clinical application value.
[中图分类号]
[基金项目]